Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1616 1633 1635 1636 1637
This examiner grants 47% of resolved cases
Abigail Louise Vanhorn is an examiner in Tech Center 1600 and Art Unit 1616, where she has handled 1219 resolved cases. Her allowance rate is 46.8%, which suggests a challenging examination process for applicants. This 46.8% rate serves as a baseline for assessing the likelihood of a grant in this specific art unit. The 1219 cases resolved by this examiner offer a robust sample size for these performance metrics.
A critical data point for this examiner is the interview lift of 22.4%, which is a significant increase in the likelihood of allowance. This figure indicates that conducting an interview is an effective strategy for moving an application toward allowance. Furthermore, the median days to allowance is 1365, suggesting a relatively long prosecution cycle. The 22.4% lift suggests that the time spent in an interview can be a pivotal investment in overcoming the challenges that contribute to the 1365-day median pendency.
Practitioners should prioritize scheduling interviews given the 22.4% lift observed across 1219 cases. While the 46.8% allowance rate indicates a rigorous review, the positive impact of verbal communication is clear. The 1365-day median to allowance should be factored into the overall strategy, with the understanding that direct dialogue is a key driver of success. This profile highlights the importance of active engagement in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19568680 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17777386 | COMPOSITIONS AND METHODS FOR ON-DEMAND RELEASE OF ANTIMICROBIAL AGENTS | Non-Final OA | University of Massachusetts |
| 15367356 | COMPOSITION FOR HAIR FRIZZ REDUCTION | Non-Final OA | The Procter & Gamble Company |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | Final Rejection | Genentech, Inc. |
| 18271536 | TREATING DISEASES AND IMPROVING NUCLEIC ACID DELIVERY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18698888 | LIPID NANOPARTICLES FOR DRUG DELIVERY TO MICROGLIA IN THE BRAIN | Non-Final OA | Massachusetts Institute of Technology |
| 18553774 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18419370 | COMPOSITIONS, METHODS AND USES FOR TREATING CYSTIC FIBROSIS AND RELATED DISORDERS | Non-Final OA | The Board of Regents of The University of Texas System |
| 18248988 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Final Rejection | SANOFI |
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | Non-Final OA | BASECURE THERAPEUTICS LLC |
| 17791504 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | Final Rejection | University of Washington |
| 18489682 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | Non-Final OA | University of Tennessee Research Foundation |
| 18218166 | Horticulture Additive | Non-Final OA | Milliken & Company |
| 17836972 | RESIDENCE STRUCTURES AND RELATED METHODS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18562095 | OLIGO-MODIFIED NUCLEOTIDE ANALOGUES FOR NUCLEIC ACID PREPARATION | Non-Final OA | ILLUMINA, INC. |
| 17906134 | COMPOSITIONS AND METHODS COMPRISING IMPROVED GUIDE RNAs | Final Rejection | Cornell University |
| 17914408 | A METHOD AND SYSTEM FOR INTRODUCING ONE OR MORE EXOGENOUS SUBSTANCES INTO AN IMMUNE CELL | Non-Final OA | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | Final Rejection | Salk Institute for Biological Studies |
| 18063982 | METHODS FOR PRODUCING IMMUNE CELL CULTURES | Non-Final OA | LONZA WALKERSVILLE, INC. |
| 18016190 | TARGETING ZNF410 FOR FETAL HEMOGLOBIN INDUCTION IN BETAHEMOGLOBINOPATHIES | Non-Final OA | The Children's Medical Center Corporation |
| 18703068 | AGT Inhibitor and Use Thereof | Non-Final OA | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy